Elevated CD147 expression is associated with shorter overall survival in non-small cell lung cancer
Metrics: PDF 468 views | HTML 754 views | ?
Xiaojun Zhang1, Tian Tian1, Xiaofeng Zhang1, Changting Liu1 and Xiangqun Fang1
1Nanlou Respiratory Diseases Department, Chinese PLA General Hospital, Beijing 100853, P. R. China
Changting Liu, email: firstname.lastname@example.org
Xiangqun Fang, email: email@example.com
Keywords: CD147, lung cancer, meta-analysis, prognosis, survival
Received: December 28, 2016 Accepted: March 13, 2017 Published: April 07, 2017
A number of studies have reported on the prognostic role of CD147 expression in non-small cell lung cancer (NSCLC); however, the results remain controversial. This study aims to investigate the impact of CD147 on the prognosis of NSCLC by means of a meta-analysis. A literature search was performed for relevant studies published before October 29, 2016. The hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were calculated as effective measures. Sensitivity analysis and publication bias examination were also conducted. Ten eligible studies with a total of 1605 patients were included in this meta-analysis. CD147 overexpression was correlated with poor overall survival (OS) (HR=1.59, 95% CI=1.32–1.91, p<0.001). Elevated CD147 expression was associated with the presence of lymph node metastasis (OR=2.31, 95% CI=1.74–3.07, p<0.001) and advanced TNM stage (OR=3.03, 95% CI=1.24–7.39, p=0.015). However, no significant association between CD147 and sex, age, differentiation, or histology was found. No evidence of significant publication bias was identified. This meta-analysis revealed that overexpression of CD147 was associated with shorter OS, the presence of lymph node metastasis and advanced TNM stage in NSCLC. Therefore, CD147 could serve as a potential prognostic marker for NSCLC.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.